# Foundayo (orforglipron) vs the shots · PepVault guides

Source: https://pepvault.app/guides/foundayo-vs-the-shots

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Foundayo (orforglipron) vs the shots: the trial numbers side by side

Reviewed November 2026 13 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Foundayo (orforglipron) is a daily GLP-1 pill, not a peptide. Its ATTAIN and ACHIEVE results beside Zepbound's SURMOUNT and Wegovy's STEP, in one table.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 13
- **Questions:** 8
- **Compounds:** 4

## The short answer

Foundayo is orforglipron, a once-daily GLP-1 pill from Eli Lilly that FDA approved for weight on April 1, 2026. It is a small chemical molecule, not a peptide, and it can be taken with or without food. On its top dose, 17.2 mg, weight fell 11.1% on average in 72 weeks, against about 21% on Zepbound and 15 to 19% on the Wegovy shot, in separate trials.

Every number checked at its primary source · Nov 20, 2026 · [13 sources](https://pepvault.app/guides/foundayo-vs-the-shots#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Strong for what it claims: large randomized phase 3 trials in people (ATTAIN-1 and -2, ACHIEVE-1 to -4, ATTAIN-MAINTAIN) and the FDA labels; no trial has compared Foundayo with Zepbound or the Wegovy shot head to head.

## What is Foundayo, and is it a peptide?

Foundayo is orforglipron, a GLP-1 receptor agonist: it switches on the receptor for GLP-1, a gut hormone that helps set appetite and how much is eaten[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). It lowers food intake, most likely through appetite, and slows the stomach, most of all after the first dose[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). In animal studies it reached the brain areas that regulate appetite and food intake[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1); that part is from animals, not people.

Look at the size: orforglipron is about a fifth of a GLP-1 peptide, which is why it absorbs like an ordinary pill.

It is not a peptide. Semaglutide (Wegovy) and tirzepatide (Zepbound) are peptides: chains of amino acids, about 4,100 and 4,800 daltons in size[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) [5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5). The stomach digests peptides the way it digests protein, so the Wegovy pill needs an empty stomach, no more than 4 ounces of plain water and a 30-minute wait before food, drinks or other pills[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7). Orforglipron is a small molecule built by chemistry, about 900 g/mol as the calcium salt in the tablet, a fifth of semaglutide's size[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). It goes in like an ordinary pill: 77% of a 0.8 mg dose reached the blood[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

So the label's routine is short: one tablet a day, swallowed whole, never more than one, with or without food[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). With food, total exposure came out 19% lower in the label's study, which the label calls not clinically relevant[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). Its half-life, the time the body takes to clear half of it, is about 29 to 49 hours[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1), against about 5 days for tirzepatide[5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5). Hence a daily pill, as the chart shows.

Try it

How Orforglipron builds up

An estimate from a half-life of about 39 hours, one dose a day for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Orforglipron in the library](https://pepvault.app/peptides/orforglipron)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault reminds you at the time you set each day and logs each tablet with one tap, so a run of missed days shows long before it reaches seven.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What is Foundayo approved for?

Weight. FDA approved Foundayo as a new molecular entity on April 1, 2026[2](https://pepvault.app/guides/foundayo-vs-the-shots#source-2). As of November 2026 (label version 10, published on DailyMed on August 13, 2026), its one approved use is to reduce excess body weight and keep it off long term, together with a reduced-calorie diet and more physical activity, in adults with obesity, or with overweight and at least one weight-related condition[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). The label advises against taking it with another GLP-1 medicine[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

It is not approved for type 2 diabetes, though the ACHIEVE trials tested it there. Zepbound, by comparison, is also approved for obstructive sleep apnoea in adults with obesity[5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5), and the Wegovy shot's label adds lowering the risk of major heart events in adults with heart disease and a liver use (MASH)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7). Which of these suits one person, and at what dose, is the prescriber's decision.

## How much weight did people lose on Foundayo compared with the shots?

Less than on Zepbound or the Wegovy shot, with one tie: in type 2 diabetes it matched the Wegovy shot's long-standing 2.4 mg dose. Every number comes from each drug's FDA label, at its top dose (for Wegovy also 2.4 mg): the average weight change, with placebo (a dummy pill or shot) in brackets, and the share who lost at least 15% of their starting weight.

| Medicine (trial) | How it's taken | Weeks | Weight change (placebo) | Lost 15% or more (placebo) |
| --- | --- | --- | --- | --- |
| **No diabetes** |  |  |  |  |
| Foundayo 17.2 mg (ATTAIN-1)[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1) | Pill, daily | 72 | −11.1% (−2.1%) | 35.9% (6.0%) |
| Zepbound 15 mg (SURMOUNT-1)[5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5) | Shot, weekly | 72 | −20.9% (−3.1%) | 70.6% (8.8%) |
| Wegovy 2.4 mg (STEP 1)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) | Shot, weekly | 68 | −14.9% (−2.4%) | 47.9% (4.8%) |
| Wegovy 7.2 mg (STEP UP)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) | Shot, weekly | 72 | −18.8% (−3.9%) | 63.8% (7.5%) |
| Wegovy pill 25 mg (OASIS 4)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) | Pill, daily | 64 | −13.6% (−2.4%) | 47% (5.5%) |
| **Type 2 diabetes** |  |  |  |  |
| Foundayo 17.2 mg (ATTAIN-2)[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1) | Pill, daily | 72 | −9.6% (−2.5%) | 25.9% (3.1%) |
| Zepbound 15 mg (SURMOUNT-2)[5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5) | Shot, weekly | 72 | −14.7% (−3.2%) | 48.0% (2.7%) |
| Wegovy 2.4 mg (STEP 2)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) | Shot, weekly | 68 | −9.6% (−3.4%) | 25.1% (4.3%) |
| Wegovy 7.2 mg (STEP UP T2D)[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) | Shot, weekly | 72 | −13.2% (−3.8%) | 39.8% (6.9%) |

Look at the gap between each pair of dots: that is the drug's effect beyond placebo, and in type 2 diabetes Foundayo's gap sits beside the Wegovy shot's at 2.4 mg, and below it at 7.2 mg.

Taking placebo away, Foundayo's top dose came out 9.0 points ahead in ATTAIN-1 and 7.1 in ATTAIN-2[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1); Zepbound's 15 mg 17.8 and 11.6[5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5); the Wegovy shot 12.4 and 6.2 at 2.4 mg, 14.9 and 9.4 at 7.2 mg[7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7).

The trials used an earlier formulation at 6, 12 and 36 mg; the label reports those groups as equivalent tablet doses, 5.5, 9 and 17.2 mg[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1), and ACHIEVE-4 states that 36 mg equals the 17.2 mg tablet[12](https://pepvault.app/guides/foundayo-vs-the-shots#source-12). ATTAIN-1's paper prints its 36 mg result as −11.2%[3](https://pepvault.app/guides/foundayo-vs-the-shots#source-3), a decimal from the label's re-analysis; ATTAIN-2's paper and label agree at −9.6%[4](https://pepvault.app/guides/foundayo-vs-the-shots#source-4).

## With this guide

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

## Is it fair to compare these trials?

Only roughly: no trial has tested Foundayo against Zepbound or the Wegovy shot. Each row is a separate trial, with its own volunteers, length (64 to 72 weeks) and way of filling in the weights of people who dropped out[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1) [5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5) [7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7).

The rows do share one thing. An estimand is the precise question a trial's main result answers. Every row is its label's intention-to-treat result: the average change in everyone randomised, whether or not they kept taking the drug, which the trials call the treatment-regimen or treatment-policy estimand[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1) [3](https://pepvault.app/guides/foundayo-vs-the-shots#source-3) [5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5) [6](https://pepvault.app/guides/foundayo-vs-the-shots#source-6) [7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7) [8](https://pepvault.app/guides/foundayo-vs-the-shots#source-8). Analyses that count only people who stayed on the drug usually come out higher, so never set one kind beside the other. The labels also say side-effect rates from different drugs' trials cannot be compared directly[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

Starting weights were close, about 100 to 113 kg (220 to 250 lb) across these trials[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1) [5](https://pepvault.app/guides/foundayo-vs-the-shots#source-5) [7](https://pepvault.app/guides/foundayo-vs-the-shots#source-7), so a percentage means similar pounds in each.

## How did orforglipron do in type 2 diabetes (ACHIEVE)?

Well on blood sugar, and it beat the semaglutide pill head to head. HbA1c is a blood test that reflects average blood sugar over about three months; the change is in percentage points. These trials use the trial doses (36 mg is the 17.2 mg tablet[12](https://pepvault.app/guides/foundayo-vs-the-shots#source-12)).

| Trial | Against | Weeks | Start HbA1c | Orforglipron | Comparator |
| --- | --- | --- | --- | --- | --- |
| ACHIEVE-1[9](https://pepvault.app/guides/foundayo-vs-the-shots#source-9) | Placebo, diet and exercise only | 40 | 8.0% | −1.24 (3 mg), −1.47 (12 mg), −1.48 (36 mg) | −0.41 |
| ACHIEVE-2[10](https://pepvault.app/guides/foundayo-vs-the-shots#source-10) | Dapagliflozin 10 mg, on metformin | 40 | 8.14% | −1.23 (3 mg), −1.50 (12 mg), −1.56 (36 mg) | −0.81 |
| ACHIEVE-3[11](https://pepvault.app/guides/foundayo-vs-the-shots#source-11) | Oral semaglutide, the drug in Rybelsus, on metformin | 52 | 8.3% | −1.71 (12 mg), −1.91 (36 mg) | −1.23 (7 mg), −1.47 (14 mg) |

ACHIEVE-3 is this guide's only trial against another GLP-1: 1,698 adults, both drugs as daily pills. Both orforglipron doses lowered HbA1c more than both semaglutide doses; 36 mg against 14 mg differed by 0.44 points[11](https://pepvault.app/guides/foundayo-vs-the-shots#source-11). The price was tolerability: stomach side effects in 59% and 58% on orforglipron against 37% and 45% on semaglutide, 9% and 10% stopping for side effects against 4% and 5%, and a larger rise in pulse, 3.7 and 4.7 beats a minute against 1.0 and 1.5[11](https://pepvault.app/guides/foundayo-vs-the-shots#source-11).

ACHIEVE-4 checked the heart. In 2,749 adults with type 2 diabetes and heart or kidney disease, followed for a median of 2 years, major heart events came in 4.2% on orforglipron and 5.0% on insulin glargine, which met the trial's test for being no worse[12](https://pepvault.app/guides/foundayo-vs-the-shots#source-12). The Wegovy pill's own routine has its own guide.

## Can Foundayo keep weight off after a shot?

In one trial, mostly. ATTAIN-MAINTAIN moved people who had lost weight on tirzepatide or semaglutide shots to daily orforglipron or a placebo pill for 52 weeks[13](https://pepvault.app/guides/foundayo-vs-the-shots#source-13). Among those whose weight had plateaued, people coming off tirzepatide kept 74.7% of their loss on orforglipron against 49.2% on placebo; people coming off semaglutide kept 79.3% against 37.6%[13](https://pepvault.app/guides/foundayo-vs-the-shots#source-13).

The trial had no group that simply stayed on the shot, and it lasted one year, so it shows the pill beats stopping, not that it matches continuing[13](https://pepvault.app/guides/foundayo-vs-the-shots#source-13). The Foundayo label sets no schedule for moving over from a shot[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

## How does the label step up the dose?

Slowly, a month at a time, to keep stomach side effects down[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). These are the label's steps, not a plan for one person:

- **0.8 mg once a day** for at least 30 days, then **2.5 mg** for at least 30 days, then **5.5 mg** [1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).
- From 5.5 mg, the dose may rise to **9 mg**, **14.5 mg** and **17.2 mg**, at least 30 days apart, by response and tolerability; 17.2 mg is the maximum[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).
- With a strong CYP3A4 inhibitor (a group of medicines that slows how the liver clears orforglipron), the label caps the dose at 9 mg a day[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).
- A missed tablet is taken as soon as possible, never doubled; after 7 or more missed days in a row, the climb restarts at a lower dose[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).
- Oral birth-control pills may work less well: the label advises a non-oral method, or adding a barrier method, for 30 days after starting and after each step-up[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

Look at where the steps turn dashed: past 5.5 mg each rise is a choice, not a schedule.

At the fastest pace that puts 17.2 mg about five months in, near the 20 weeks Zepbound's climb to 15 mg took in SURMOUNT-1[6](https://pepvault.app/guides/foundayo-vs-the-shots#source-6).

<!--promo-->

PepVault reminds you at the time you set each day and logs each tablet with one tap, so a run of missed days shows long before it reaches seven. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-foundayo-vs-the-shots-inline&mt=8)

<!--/promo-->

<!--promo-->

Its weight and side-effect logs keep each month's step beside how you felt, ready for the prescriber's next decision. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-foundayo-vs-the-shots-inline&mt=8)

<!--/promo-->

## What side effects come with Foundayo?

Mostly stomach effects, highest during the step-ups and easing over time[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). In the label's pool of both weight trials, on 17.2 mg against placebo: nausea 35% against 10%, diarrhoea 25% against 11%, constipation 24% against 9% and vomiting 24% against 4%[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). Most stomach effects were mild or moderate, and 10% on 17.2 mg stopped because of side effects, against 3% on placebo[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). Smaller, slower meals are the usual advice, and the label asks for steady fluids when stomach effects hit[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). The full list is on our orforglipron side-effects page.

Like the shots, it carries a boxed warning on thyroid C-cell tumours, worded differently: the rodent tumours behind the shots' warning come from the GLP-1 receptor acting in rats and mice, and orforglipron does not act in those animals; it caused no tumours there, and whether the finding matters for people has not been determined[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1). It is not for anyone with a personal or family history of medullary thyroid cancer or MEN 2[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

**Commonly reported:** liking that the tablet goes down with breakfast or coffee, unlike the Wegovy pill's morning wait; queasiness or fullness for a few days after each monthly step; and appetite quieting within the first weeks.

**When to get help** Severe stomach pain that does not settle, with or without vomiting, can be pancreatitis, which the label lists, so that is the moment to get medical help the same day[1](https://pepvault.app/guides/foundayo-vs-the-shots#source-1).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. FOUNDAYO (orforglipron) tablets prescribing information, DailyMed, SPL version 10, August 13, 2026 [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62)
2. Drugs@FDA: NDA 220934, FOUNDAYO tablets, original approval April 1, 2026 [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934)
3. Wharton S et al.; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025. [PubMed 40960239](https://pubmed.ncbi.nlm.nih.gov/40960239/)
4. Horn DB et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3 trial. Lancet. 2026. [PubMed 41275875](https://pubmed.ncbi.nlm.nih.gov/41275875/)
5. ZEPBOUND (tirzepatide) prescribing information, DailyMed, SPL version 40, September 2, 2026 [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
6. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. [PubMed 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
7. WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed, SPL version 19, June 30, 2026 [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
8. Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. [PubMed 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
9. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025. [PubMed 40544435](https://pubmed.ncbi.nlm.nih.gov/40544435/)
10. Orforglipron compared with dapagliflozin in adults with type 2 diabetes on metformin (ACHIEVE-2): a phase 3 trial. Lancet. 2026. [PubMed 42259339](https://pubmed.ncbi.nlm.nih.gov/42259339/)
11. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026. [PubMed 41765029](https://pubmed.ncbi.nlm.nih.gov/41765029/)
12. Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes (ACHIEVE-4). Lancet. 2026. [PubMed 42815506](https://pubmed.ncbi.nlm.nih.gov/42815506/)
13. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. [PubMed 42120723](https://pubmed.ncbi.nlm.nih.gov/42120723/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)

Compounded semaglutide and tirzepatide are not FDA-approved. What compounding is, what the FDA decided and when, and how a vial differs from a brand pen.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Orforglipron Studied range: 0.8–17.2 mg](https://pepvault.app/peptides/orforglipron)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) Studied range: 1.5–25 mg](https://pepvault.app/peptides/semaglutide-oral)

## Related guides

- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
